All News

Patients with non–small cell lung cancer previously treated with multiple lines of therapy may benefit from treatment with patritumab deruxtecan.

Treatment with zanubrutinib and obinutuzumab improved outcomes in patients with relapsed/refractory follicular lymphoma vs obinutuzumab monotherapy.

A post-hoc analysis of the phase 3 TITAN trial revealed potential biomarkers that may predict overall survival in patients with metastatic castration-resistant prostate cancer receiving apalutamide plus androgen deprivation therapy.

Dose reductions of ribociclib administered during the phase 2 MONALEESA-2 trial did not have an impact on overall survival for patients with hormone receptor–positive, HER2-negative advanced breast cancer.

In patients with colorectal cancer and synchronous unresectable metastases, resection of the primary tumor before systemic therapy did not result in an extension of overall survival.

Results from a correlative analysis conducted with 3-years of follow-up showed pembrolizumab monotherapy resulted in the greatest long-term survival benefit in patients with non–small cell lung cancer and a PD-L1 tumor proportion score of 90% or more.

Bevacizumab plus FOLFOXIRI was superior to bevacizumab plus FOLFOX or FOLFIRI in terms of efficacy but was more toxic in certain patients with initially unresectable colorectal cancer liver metastases.

Patients with previously untreated, locally advanced stage 3 non–small cell lung cancer continue to derive a benefit from pembrolizumab with concurrent chemoradiation followed by additional pembrolizumab after more than 2 years of follow-up.

Radiotherapy can be avoided after surgery in certain patients with low-grade luminal A breast cancer who have low Ki67 expression and no positive lymph nodes, according to data from 2022 ASCO.

Unlike with enzalutamide, it appears darolutamide does not affect systemic exposure of cabazitaxel in patients with metastatic castration-resistant prostate cancer.

An analysis presented at 2022 ASCO reveals a potential correlation between CDKN2A/B as well as cell cycle pathway alterations and brain metastases in non–small cell lung cancer.

Progression-free survival and overall survival were enhanced with the use of bevacizumab plus first-line chemotherapy in ovarian clear cell carcinoma.

Patients with acquired ESR1 mutations after disease progression and post-treatment for locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer may benefit from treatment with lasofoxifene in combination with abemaciclib.

At a minimum follow-up of 3 years, an improvement in overall survival was seen in patients with metastatic non–small cell lung cancer treated with nivolumab and ipilimumab in combination with chemotherapy.

A neoadjuvant and postsurgical treatment regimen involving ruxolitinib and chemotherapy appeared to boost progression-free survival in patients with stage III and IV ovarian cancer.

Results from the phase 3 KEYNOTE-826 trial show a significant survival benefit with pembrolizumab plus chemotherapy with or without bevacizumab in most patient subgroups with persistent, recurrent, or metastatic cervical cancer.

Results of a matching-adjusted indirect comparison study showed that patients with HR-positive/HER2–negative advanced breast cancer treated with ribociclib and an aromatase inhibitor were more likely to have better symptom-related quality of life than patients who received abemaciclib and an aromatase inhibitor.

Results from the phase 3 PEARLS/KEYNOTE-091 trial showed improved disease-free survival with pembrolizumab vs placebo for patients with completely resected early-stage non–small cell lung cancer, without regard surgical treatment, extent of disease, or adjuvant chemotherapy.

The 5-year analysis of the phase 3 CheckMate 227 trial showed consistent, long-term survival with nivolumab plus ipilimumab for metastatic non–small cell lung cancer.

A sustained progression-free survival benefit was observed with nivolumab plus relatlimab-rmbw vs nivolumab alone in the phase 2/3 RELATIVITY-047 trial in treatment-naïve, unresectable or metastatic melanoma.

Factors associated with early discontinuation of adjuvant abemaciclib for hormone receptor—positive, HER2-negative, node-positive high-risk early breast cancer inform future treatment monitoring.

BRAF V600 mutation–positive pediatric low-grade glioma positively responds to combination treatment with dabrafenib plus trametinib, according to data presented at 2022 ASCO.

In a MET-unselected population of PD-L1–positive non–small cell lung cancer, the addition of capmatinib to pembrolizumab did not lead to more responses but increased toxicity.

The ATHENA-MONO trial showed a significant improvement in progression-free survival when patients with platinum-sensitive ovarian cancer were treated with maintenance rucaparib vs placebo in the first-line setting, regardless of HRD status.

The results, however, showed that remaining on mobocertinib may be warranted for patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer that has progressed after mobocertinib treatment.

Preliminary findings of data from the phase 1/2 LUPER study demonstrate that treatment with lurbinectedin combined with pembrolizumab elicits promising efficacy in patients with metastatic small-cell lung cancer that has failed to respond to chemotherapy.

Patients with TRK fusion–positive central nervous system tumors were observed to have increased efficacy and safety when treated with larotrectinib at long-term follow-up.

Subgroup analysis of the RE-MIND trial support use of tafasitamab plus lenalidomide to treat high-risk diffuse large B-cell lymphoma.

Biagio Ricciuti, MD, spoke about patients with non–small cell lung cancer with a very high PD-L1 tumor proportion score of 90% or more who were treated with first-line pembrolizumab monotherapy.

Data presented at 2022 ASCO reveals PET-imaging characteristics linked with 177Lu-PSMA-617 efficacy in metastatic castration-resistant prostate cancer.